Differences in biomarkers and molecular pathways according to age for patients with HFrEF
| Autor: | Marco Metra, Gerasimos Filippatos, Bernadet T. Santema, Iziah E Sama, Wouter Ouwerkerk, Chim C. Lang, Joseph-Pierre Aboumsallem, Adriaan A. Voors, Samani J Nilesh, Sylwia M. Figarska, Stefan D. Anker, Dirk J. van Veldhuisen, John G.F. Cleland, Kenneth Dickstein, Faiez Zannad, João Pedro Ferreira, Rudolf A. de Boer, Leong L. Ng |
|---|---|
| Přispěvatelé: | Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), National Heart Centre Singapore (NHCS), University of Amsterdam [Amsterdam] (UvA), University Medical Center Groningen [Groningen] (UMCG), Ninewells Hospital and Medical School [Dundee], University of Dundee, Department of Cardiovascular Sciences [Leicester], University of Leicester, University Hospitals Leicester, Berlin-Brandenburg Center for Regenerative Therapies [Berlin, Germany], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Stavanger University Hospital, Department of Cardiology, Spedali Civili di Brescia, University of Glasgow, National and Kapodistrian University of Athens (NKUA), BIOSTAT-CHF was funded by the European Commission (FP7-242209-BIOSTAT-CHF). Further financial support was provided by Roche diagnostics. JPF and FZ are supported by the French PIA project 'Lorraine Université d’Excellence' GEENAGE (ANR-15-IDEX-04-LUE) programmes, and the Contrat de Plan Etat Région Lorraine and FEDER IT2MP., ANR-15-IDEX-0004,LUE,Isite LUE(2015), European Project: 242209,EC:FP7:HEALTH,FP7-HEALTH-2009-single-stage,BIOSTAT-CHF(2010), Epidemiology and Data Science, Cardiovascular Centre (CVC) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Proteomics 0301 basic medicine Oncology Proteome Physiology 030204 cardiovascular system & hematology medicine.disease_cause Ventricular Function Left 0302 clinical medicine Risk Factors Medicine heart failure with reduced ejection fraction Protein Interaction Maps Aged 80 and over Ejection fraction Age Factors Middle Aged Prognosis Pathophysiology 3. Good health Europe Cohort HEART-FAILURE Female Cardiology and Cardiovascular Medicine medicine.medical_specialty MODELS Risk Assessment Biological pathway 03 medical and health sciences WFDC2 [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system Predictive Value of Tests Physiology (medical) Internal medicine Humans aging biological age biomarkers chronological age Aged business.industry Reproducibility of Results Stroke Volume medicine.disease Ageing 030104 developmental biology Heart failure business Carcinogenesis Heart Failure Systolic |
| Zdroj: | Cardiovascular Research Cardiovascular Research, Oxford University Press (OUP), 2020, ⟨10.1093/cvr/cvaa279⟩ Cardiovascular research, 117(10), 2228-2236. Oxford University Press Cardiovascular Research, 117(10), 2228-2235. Oxford University Press |
| ISSN: | 0008-6363 |
| Popis: | Aims:\ud Elderly patients with heart failure with reduced ejection fraction (HFrEF) have worse prognosis and less often receive guideline-recommended therapies. We aim to better understand the underlying pathophysiological processes associated with aging in HFrEF potentially leading to targeted therapies in this vulnerable population.\ud \ud Methods and Results:\ud From a panel of 363 cardiovascular biomarkers available in 1,611 patients with HFrEF in the BIOSTAT-CHF index cohort and cross-validated in 823 patients in the BIOSTAT-CHF validation cohort, we tested which biomarkers were dysregulated in patients aged > 75yr versus |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|